With the development and advancement of exosome engineering technology, the identification of circRNAs that can affect PD-1/PD-L1 expression in GC cells and their transfer to target cells through engineering-engineered exosomes, thereby increasing the sensitivity of targeted drug therapy, holds great potential for targeted therapy in GC. This evidence concerns the gene CD274 and gastric cancer.